Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Feb 26, 2024•almost 2 years ago
Acquiring Company
Bristol Myers Squibb
Acquired Company
RayzeBio, Inc.
LawrencevilleSan DiegoManufacturingHealth CareDescription
Bristol Myers Squibb has successfully completed the acquisition of RayzeBio, Inc., a biopharmaceutical company known for its pioneering work in the development of radiopharmaceutical therapeutics (RPTs) for the treatment of solid tumors. This acquisition bolsters Bristol Myers Squibb's oncology pipeline, particularly in the area of RPTs, and is expected to unlock new opportunities for growth and innovation in the coming years.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed